Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24.4K Buy
+97
New +$20.9K ﹤0.01% 282
2023
Q2
– Sell
-277
Closed -$44.1K – 315
2023
Q1
$44.1K Sell
277
-372
-57% -$56.9K ﹤0.01% 191
2022
Q4
$105K Sell
649
-162
-20% -$24.8K ﹤0.01% 147
2022
Q3
$116K Sell
811
-676
-45% -$97K ﹤0.01% 149
2022
Q2
$228K Sell
1,487
-15,940
-91% -$2.44M ﹤0.01% 126
2022
Q1
$2.83M Buy
17,427
+1,334
+8% +$194K 0.02% 101
2021
Q4
$2.18M Sell
16,093
-57
-0.4% -$6.73K 0.02% 124
2021
Q3
$1.75M Buy
16,150
+15,181
+1,567% +$1.73M 0.01% 142
2021
Q2
$109K Sell
969
-47
-5% -$5.29K ﹤0.01% 314
2021
Q1
$110K Sell
1,016
-615
-38% -$65.8K ﹤0.01% 212
2020
Q4
$174K Buy
1,631
+10
+0.6% +$961 ﹤0.01% 174
2020
Q3
$142K Buy
1,621
+1,018
+169% +$95.8K ﹤0.01% 145
2020
Q2
$59K Buy
603
+183
+44% +$16.1K ﹤0.01% 186
2020
Q1
$32K Buy
420
+63
+18% +$5.37K ﹤0.01% 205
2019
Q4
$32K Buy
357
+353
+8,825% +$29.3K ﹤0.01% 211
2019
Q3
$0 Sell
4
-129
-97% -$8.84K ﹤0.01% 403
2019
Q2
$10K Buy
+133
New +$10.5K ﹤0.01% 293

Other funds holding ABBV

Altshuler Shaham's ABBV Position: Q2 2026 in Review

Altshuler Shaham opened a new position in AbbVie (ABBV) in Q2 2026: 97 shares worth $24.4K. The stake represents ﹤0.01% of the portfolio and ranks #282 among its holdings. This is a return to the name: Altshuler Shaham previously reported a position in ABBV as recently as Q1 2023.

Altshuler Shaham first reported a position in ABBV in Q2 2019 and has held it in 17 quarters since. The position peaked at $2.83M in Q1 2022. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Altshuler Shaham held 97 shares of AbbVie worth $24.4K as of Q2 2026.
  • AbbVie was a new Altshuler Shaham position in Q2 2026.
  • AbbVie made up ﹤0.01% of Altshuler Shaham's portfolio in Q2 2026, its #282 holding.
  • Altshuler Shaham first reported a position in AbbVie in Q2 2019 and has held it in 17 quarters since.
  • Altshuler Shaham's AbbVie position peaked at $2.83M in Q1 2022.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Altshuler Shaham's 13F filing for Q2 2026, filed 12 Aug 2026.